$130.54 – $303.99
Ongentys (opicapone) is an innovative and effective treatment for the management of motor and non-motor symptoms in PD.
Ongentys’s long-acting, once-daily dosing regimen, and its inhibition of COMT enzyme activity, enhances the stability and efficacy of levodopa therapy, resulting in prolonged “on” time and reduced “off” time without troublesome dyskinesia.
Ongentys (opicapone) is a novel, long-acting alternative treatment for Parkinson’s disease (PD), approved by the US Food and Drugs Administration (FDA) in June 2020, and by the European Medicines Agency (EMA) in April 2016. Ongentys is indicated for adult patients with PD experiencing end-of-dose “wearing-off” motor fluctuations and optimised dopaminergic therapy was developed and branded by Neurocrine Biosciences, in collaboration with Portuguese pharma company, BIAL.
PD is a chronic, progressive movement disorder, characterised by the degeneration of dopaminergic neurons in the substantia nigra, a region of the brain that influences motor control. This demise causes a deficiency of dopamine, a neurotransmitter involved in the regulation of movement, cognition, mood, and behaviour. As a result, PD patients often experience motor symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Currently, there is no cure for PD, and treatments are aimed at mitigating the symptoms and improving the patient’s quality of life.
Ongentys is an inhibitor of catechol-O-methyltransferase (COMT), an enzyme which breaks down dopamine, levodopa, and other catecholamines in the brain and peripheral tissues. opicapone extends the half-life of levodopa, a precursor of dopamine, and reduces the fluctuations in plasma concentrations of levodopa and its metabolites. This creates more constant delivery of the drug to the brain, resulting in more stable control of PD symptoms.
opicapone is taken orally as a capsule, once daily, at bedtime, in combination with levodopa/carbidopa or levodopa/benserazide. The usual starting dose is 25 mg, which can be increased to 50-50 mg after one week of treatment based on individual response and tolerability. According to clinical trials, opicapone significantly increased “on” time without dyskinesia, reduced off time, and improved patients’ motor symptoms, compared to placebo. In a six-month phase III trial, opicapone was shown to increase “on” time without troublesome dyskinesia by 1.06 hours compared to placebo. This effect was sustained in a two-year extension study and was seen regardless of the patient’s age, sex, disease duration, or levodopa dose.
Moreover, opicapone also had a favourable impact on non-motor symptoms in PD, such as sleep quality, daytime sleepiness, and cognitive function. In a 14-week phase III trial, Ongentys significantly improved the Epworth Sleepiness Scale (ESS) score, indicating less excessive daytime sleepiness than placebo. Furthermore, opicapone improved the Scales for Outcomes in Parkinson’s disease – Cognitive function (SCOPA-COG) global score and the SCOPA-COG verbal fluency domain score, suggesting a cognitive-enhancing effect. These results are encouraging, given that cognitive impairment is a common and debilitating aspect of PD, affecting up to 25% of patients.
Unlike other COMT inhibitors, such as entacapone and tolcapone, Ongentys does not require dosing with every levodopa intake, due to its once-daily dosing regimen. Furthermore, opicapone has a low potential for hepatic toxicity, a common adverse effect of tolcapone, which led to its withdrawal or restriction in some countries. Although Ongentys might cause mild to moderate adverse effects, such as dyskinesia, hallucinations, constipation, or orthostatic hypotension, they were reported at similar rates as placebo. The most common side effect of Ongentys is an increase in the liver enzyme, alanine aminotransferase (ALT), which can be monitored through regular liver function tests.
With its improved efficacy and tolerability profile, Ongentys represents a valuable addition to the armamentarium of drugs for the management of PD. Ongentys can provide PD patients with a more flexible, convenient, and reliable treatment option, reducing the burden of their symptoms and improving their overall well-being. Furthermore, Ongentys’s potential to ameliorate cognitive function and sleep disturbances can enhance the patient’s quality of life further. Although Ongentys is not a cure for PD, its novel mechanism of action and advanced pharmacokinetic profile hold promise for the future development of therapies for PD and other neurological disorders.
In conclusion, Ongentys’s potential to improve sleep quality and cognitive performance, coupled with its safety profile, make it a welcome addition to the treatment options available for PD patients. With further studies, Ongentys’s benefits might extend to other patient populations with motor fluctuations, such as those with atypical parkinsonism or advanced PD. Ongentys is an exciting and transformative drug that represents not only hope but also a significant advance in the management of PD, bringing us one step closer to a cure.
30 capsules of 50 mg, 90 capsules of 50 mg
(Traduit par Google) Excellent service, informations rapides et précises, attitude professionnelle et gentillesse de la personne de contact. Je recommande vivement
Excellent service, fast and accurate information, professional attitude and kindness from contact person. I highly recommend
Celina Waleśkiewicz –
I greatly appreciate a very professional and supportive serice I experienced during the whole ordering process.
I was in continues contact with Marta and Lieschen, who patiently responded to each and every question and guided me through the procedure. Once again many , many thanks!
Andreea Codreanu –
I want to recommend this organization,all personal very reliable,professional and always on time.Karolina is great,she helped me extremelly and ill be always grateful!! Thank you!!
George Harris –
Very efficient and trustworthy service that provides my partner with a life extending drug which would not otherwise be available in the UK. Customer service is second-to-none and all my enquiries are usually answered within a few hours (a special shout out to Maxwell.) There are obviously many companies selling snake oil online, but I can attest that The pharma medwork are 100% reputable and professional in all my dealings with them.
Edit: I’ve unfortunately had to downgrade my rating. I am still grateful for the drug that TSM supplies to my partner, however their service has undoubtedly become worse in recent months. Delivery times are much longer and unexpected delays are commonplace. Communication is also slow, and I find I have to chase things up constantly rather than being kept informed. Often my phone calls go unanswered. Recently I was told our shipment would arrive within 10 days, and that was 19 days ago. This means we are delayed in taking the medicine and, most importantly, my partner’s health is compromised.
We pay 300 euros per shipment on ‘handling fees’, and do expect a commensurate service.